SCHEMBL3074203

SCHEMBL3074203

N#Cc1ccc(C#Cc2nc(-c3ccncc3F)c(-c3cccnc3)nc2N)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.43
KDM4E B2RXH2 8/20 0.41
GAA P10253 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
GLA P06280 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP3A4 P08684 1/20 0.40
ADORA2B P29275 1/20 0.40
CYP2C19 P33261 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
CYP11B1 P15538 3/20 0.39
CYP17A1 P05093 1/20 0.39
NPY5R Q15761 1/20 0.36
CYP19A1 P11511 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
IKBKB O14920 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3058442 0.92 KDM4E (0.41) KDM4EGAAALDH1A1HPGDGLA
SCHEMBL3063995 0.89 CYP3A4 (0.42) KDM4EGAAALDH1A1HPGDGLA
SCHEMBL3066885 0.81 ADORA2B (0.42) KDM4EGAAALDH1A1HPGDGLA
SCHEMBL3068229 0.81 ADORA2B (0.47) KDM4EGAAALDH1A1HPGDGLA
SCHEMBL3058845 0.80 ADORA2B (0.51) KDM4EGAAALDH1A1HPGDGLA
SCHEMBL3058556 0.75 ADORA2B (0.47) KDM4EGAAALDH1A1HPGDGLA
SCHEMBL3061789 0.73 CCNB2 (0.47) CYP11B2KDM4EGAAALDH1A1HPGD
SCHEMBL4696611 0.73 CYP19A1 (0.47) CYP11B2KDM4EGAAALDH1A1HPGD
SCHEMBL13090347 0.70 ADORA2B (0.49) ALDH1A1CYP3A4ADORA2BCYP2C19ADORA2A
SCHEMBL21934675 0.70 ADORA2B (0.48) KDM4EGAAALDH1A1HPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
EP-1922313-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS Laboratorios Almirall, S.A. (ES) 2008-05-21 EP disclosed
WO-2007017096-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA3 CYP11B2 92/4885KDM4E 4367/4885GAA 3452/4885
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2B, ADORA2A, ADORA1 CYP11B2 178/4885KDM4E 3671/4885GAA 4594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.